Cross-Dock Clinical Supply Solutions for a Post-Brexit Europe
Minimize Risks to Continuity of Supply in European and UK Studies
Since the UK voted to leave the EU in 2016, Catalent has worked diligently alongside customers to ensure that we can maintain continuity of supply to clinical trial participants across Europe following Brexit.
Catalent Clinical Supply Services offers sponsors preparing for Brexit:
- Access to the industry-leading experts from our Brexit Strategic Planning Team to best support your risk mitigation activities
- A network of 9 GMP clinical supply facilities, 3 of which have been established and working together in the UK and EU for 20+ years to support clinical supply chains across Europe and the globe
- Brexit solutions that can produce efficiencies in mitigating the risk to clinical supply chain continuity
- A full range of comprehensive clinical supply services, available through all our UK and EU sites